Gerrit Los

5.5k citations

94 papers · 4.1k indexed · 2 hit papers · h-index 33

Impact in

Oncology top 1%
- PARP inhibition in cancer therapy
- Lung Cancer Research Studies
Reproductive Medicine top 1%
- Ovarian cancer diagnosis and treatment

Papers in ⓘ

Oncology 35
- HER2/EGFR in Cancer Research 7
- Cancer Treatment and Pharmacology 6
Pathology and Forensic Medicine 20
- Chemotherapy-induced organ toxicity mitigation 13

Co-authors: J. G. McVie (13 shared papers)Maria E. Arango (6 shared papers)James G. Christensen (4 shared papers)Barbara Mroczkowski (3 shared papers)P.H.A. Mutsaers (6 shared papers)Helen Y. Zou (3 shared papers)Shinji Yamazaki (3 shared papers)Qiuhua Li (3 shared papers)
Journals: Cancer Research (11 papers)Cancer Chemotherapy and Pharmacology (9 papers)British Journal of Cancer (6 papers)Molecular Cancer Therapeutics (5 papers)Journal of Clinical Oncology (4 papers)
Partner nations: United States Netherlands United Kingdom

In The Last Decade

Gerrit Los

93 papers receiving 4.0k citations

Hit Papers

align trajectories log scale

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma 2007 · 513 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2007 Molecular Cancer Therapeutics
2007 Cancer Research

Peers

Countries citing papers authored by Gerrit Los

Since Specialization

Citations

This map shows the geographic impact of Gerrit Los's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerrit Los with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerrit Los more than expected).

Fields of papers citing papers by Gerrit Los

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerrit Los. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerrit Los. The network helps show where Gerrit Los may publish in the future.

Co-authors

The 25 scholars most cited alongside Gerrit Los, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gerrit Los Line = papers co-authored together Gerrit Los links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 94 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms Cancer Research ·Helen Y. Zou, Qiuhua Li, Joseph H. Lee, Maria E. Arango, Scott R. McDonnell, Shinji Yamazaki, Tatiana Koudriakova, Gordon Alton, Jingrong Jean Cui, Pei-Pei Kung, Mitchell D. Nambu, Gerrit Los, Steven L. Bender, Barbara Mroczkowski, James G. Christensen Hit paper breakdown →	2007	593
2	Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma Molecular Cancer Therapeutics ·James G. Christensen, Helen Y. Zou, Maria E. Arango, Qiuhua Li, Joseph H. Lee, Scott R. McDonnell, Shinji Yamazaki, Gordon Alton, Barbara Mroczkowski, Gerrit Los Hit paper breakdown →	2007	513
3	Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors Clinical Cancer Research ·Asima Mukhopadhyay, Ahmed Elattar, Aiste Cerbinskaite, Sarah Wilkinson, Yvette Drew, Suzanne Kyle, Gerrit Los, Zdeněk Hostomský, Richard J. Edmondson, Nicola J. Curtin	2010	207
4	Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2 JNCI Journal of the National Cancer Institute ·Yvette Drew, Evan A. Mulligan, Wan-Tse Vong, Huw D. Thomas, Samra Kahn, Suzanne Kyle, Asima Mukhopadhyay, Gerrit Los, Zdeněk Hostomský, Elizabeth Ruth Plummer, Richard J. Edmondson, Nicola J. Curtin	2010	191
5	Pentetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy Cancer Chemotherapy and Pharmacology ·Gerrit Los, Els M.E. Verdegaal, P.H.A. Mutsaers, J. G. McVie	1991	148
6	Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer. Journal of Clinical Oncology ·K. Thomas Robbins, Anna Maria Storniolo, Charles W. Kerber, Daniel Vicario, Stephen L. Seagren, Michael Shea, Catherine Hanchett, Gerrit Los, Stephen B. Howell	1994	125
7	Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. PubMed ·Gerrit Los, P.H.A. Mutsaers, (unknown), Glenn S. Baldew, Peter W. de Graaf, J. G. McVie	1989	117
8	Platinum distribution inintraperitoneal tumors afterintraperitoneal cisplatin treatment Cancer Chemotherapy and Pharmacology ·Gerrit Los, P.H.A. Mutsaers, Willem J. M. Lenglet, Glenn S. Baldew, J. G. McVie	1990	114
9	Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin British Journal of Cancer ·Gerrit Los, M. van Vugt, Herbert M. Pinedo	1994	105
10	Reversal of cisplatin resistance with a BH3 mimetic, (−)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL Molecular Cancer Therapeutics ·Joshua A. Bauer, Douglas K. Trask, Bhavna Kumar, Gerrit Los, J. Gonzalez Castro, Julia Shin-Jung Lee, Jianyong Chen, Shaomeng Wang, Carol R. Bradford, Thomas E. Carey	2005	103
11	Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats European Journal of Cancer and Clinical Oncology ·Gerrit Los, Peter Sminia, Jan Wondergem, P.H.A. Mutsaers, Jaap Havemen, Daan ten Bokkel Huinink, O. A. G. Smals, Dionisio Gonzalez-Gonzalez, J. G. McVie	1991	98
12	Diazonamide A and a Synthetic Structural Analog: Disruptive Effects on Mitosis and Cellular Microtubules and Analysis of Their Interactions with Tubulin Molecular Pharmacology ·Zobeida Cruz‐Monserrate, Hélène C. Vervoort, Ruoli Bai, David Newman, Stephen B. Howell, Gerrit Los, Jeffrey T. Mullaney, Michael D. Williams, George R. Pettit, William Fenical, Ernest Hamel	2003	95
13	Structure-based design of novel human Pin1 inhibitors (I) Bioorganic & Medicinal Chemistry Letters ·Chuangxing Guo, Xinjun Hou, Liming Dong, Eleanor Dagostino, S.E. Greasley, Rose Ann Ferre, Joseph Marakovits, M. Catherine Johnson, David A. Matthews, Barbara Mroczkowski, Hans E. Parge, Todd VanArsdale, Ian Popoff, Joseph Piraino, Stephen A. Margosiak, James Thomson, Gerrit Los, Brion W. Murray	2009	91
14	A Novel Antiandrogen, Compound 30, Suppresses Castration-Resistant and MDV3100-Resistant Prostate Cancer Growth In Vitro and In Vivo Molecular Cancer Therapeutics ·Hidetoshi Kuruma, Hiroaki Matsumoto, Masaki Shiota, Jennifer L. Bishop, François Lamoureux, Christian Thomas, David M. Briere, Gerrit Los, Martin Gleave, Andrea Fanjul, Amina Zoubeidi	2013	86
15	Selenium-induced protection against cis-diamminedichloroplatinum(II) nephrotoxicity in mice and rats. PubMed ·Glenn S. Baldew, C Hamer, Gerrit Los, Nico Vermeulen, J J de Goeij, J. G. McVie	1989	81
16	Non-invasive measurement of chemotherapy drug concentrations in tissue: preliminary demonstrations ofin vivomeasurements Physics in Medicine and Biology ·Judith R. Mourant, Tamara M. Johnson, Gerrit Los, Irving J. Bigio	1999	77
17	A Novel Organ Preservation Protocol for Advanced Carcinoma of the Larynx and Pharynx Archives of Otolaryngology - Head and Neck Surgery ·Robbins Kt, James Fontanesi, Frank S. H. Wong, Daniel Vicario, Stephen L. Seagren, Parvesh Kumar, Robert A. Weisman, Phillip Pellitteri, J. Regan Thomas, Pamela Flick, R. L. Palmer, Alva B. Weir, Charles W. Kerber, Thomas Murry, R. Ferguson, Gerrit Los, Lisa A. Orloff, S B Howell	1996	70
18	A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. PubMed ·Gerrit Los, O. A. G. Smals, Marianne J.H. van Vugt, M. Van Der Vlist, L. Den Engelse, J. G. McVie, H. M. Pinedo	1992	62
19	Loss of DNA Mismatch Repair: Effects on the Rate of Mutation to Drug Resistance JNCI Journal of the National Cancer Institute ·Maida M. de las Alas, Stefan Aebi, Daniel Fink, Stephen B. Howell, Gerrit Los	1997	59
20	PF-03732010: A Fully Human Monoclonal Antibody against P-Cadherin with Antitumor and Antimetastatic Activity Clinical Cancer Research ·Cathy C. Zhang, Zhengming Yan, Qin Zhang, Kyle Kuszpit, Kenneth Zasadny, Ming Qiu, Cory L. Painter, Anthony Wong, Eugenia Kraynov, Maria E. Arango, Pramod P. Mehta, Ian Popoff, Gerald F. Casperson, Gerrit Los, Steve Bender, Kenna Anderes, James G. Christensen, Todd VanArsdale	2010	58

About Gerrit Los

Gerrit Los is a scholar working on Oncology, Pathology and Forensic Medicine, Molecular Biology, Cancer Research and Biophysics, having authored 94 papers that have together received 4.1k indexed citations. Recurring topics across this work include Chemotherapy-induced organ toxicity mitigation (13 papers), DNA Repair Mechanisms (12 papers), Intraperitoneal and Appendiceal Malignancies (11 papers), Cancer therapeutics and mechanisms (8 papers), HER2/EGFR in Cancer Research (7 papers), Cancer Treatment and Pharmacology (6 papers), Melanoma and MAPK Pathways (6 papers) and Microtubule and mitosis dynamics (6 papers). The work is most often cited by research in Oncology (1.7k citations), Reproductive Medicine (505 citations), Otorhinolaryngology (181 citations), Hepatology (291 citations) and Pulmonary and Respiratory Medicine (1.0k citations). Gerrit Los has collaborated with scholars based in United States, Netherlands and United Kingdom. Frequent co-authors include J. G. McVie, Maria E. Arango, James G. Christensen, Barbara Mroczkowski, P.H.A. Mutsaers, Helen Y. Zou, Shinji Yamazaki, Qiuhua Li, Joseph H. Lee and Gordon Alton. Their work appears in journals such as Cancer Research, Cancer Chemotherapy and Pharmacology, British Journal of Cancer, Molecular Cancer Therapeutics and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact